Global EUS-Guided Fine Needle Biopsy Market Size By Type (Enteral Endoscopic Ultrasound Needles, Bronchial Endoscopic Ultrasound Needles), By Application (Hospitals, Clinics), By Region, And Segment F...

The Global EUS-Guided Fine Needle Biopsy (FNB) Market was valued at USD 324 million in 2023 and is projected to reach USD 609 million by 2031, growing at a CAGR of 8.4% during the forecast period of 2023–2031. This growth is attributed to the rising incidence of gastrointestinal cancers, increasing preference for minimally invasive diagnostic procedures, and advancements in endoscopic ultrasound (EUS) technologies. EUS-guided FNB is widely used to obtain high-quality tissue samples from deep-seated lesions, enabling more accurate histopathological diagnoses and improved patient outcomes.

Drivers:

1. Increasing Prevalence of Gastrointestinal and Pancreatic Disorders

The rising global burden of cancers and pancreatic lesions is significantly boosting the demand for EUS-guided diagnostic methods. FNB offers superior sample quality, facilitating precise cancer staging and therapy planning.

2. Technological Advancements in EUS and Needle Design

Continuous innovations, such as the introduction of core biopsy needles and real-time imaging guidance, are enhancing the accuracy, safety, and efficiency of FNB procedures.

3. Growing Preference for Minimally Invasive Diagnostics

Patients and clinicians alike are increasingly favoring procedures that reduce recovery times and risks, positioning EUS-FNB as a preferred diagnostic tool over surgical biopsies.

Restraints:

1. High Cost of Equipment and Procedures

The upfront investment required for EUS equipment and the procedural costs associated with FNB can be substantial, limiting accessibility, especially in developing regions.

2. Limited Availability of Skilled Endoscopists

The procedure requires high expertise, and a shortage of trained professionals in low-resource settings continues to hinder market expansion.

Opportunity:

1. Expansion in Emerging Economies

Countries in Asia-Pacific and Latin America are witnessing increasing investments in healthcare infrastructure, opening lucrative avenues for the adoption of EUS-FNB.

2. Integration with AI and Real-time Imaging

The integration of artificial intelligence with EUS systems can significantly enhance diagnostic accuracy, while real-time imaging ensures targeted tissue acquisition—driving clinical adoption.

Market by System Type Insights:

Based on system type, core biopsy needles dominated the market in 2023 due to their ability to obtain high-quality tissue architecture, making them ideal for histopathological evaluation. Aspiration needles continue to be widely used for cytological sampling but are expected to grow at a slower pace due to evolving clinical preferences for histology-grade samples.

Market by End-use Insights:

In terms of end-use, hospitals accounted for the largest market share in 2023, owing to the availability of advanced endoscopic equipment and skilled personnel. The ambulatory surgical centers (ASCs) segment is expected to witness significant growth, driven by faster patient turnover and cost-effective procedural models.

Market by Regional Insights:

North America led the global market in 2023, supported by strong healthcare infrastructure, higher cancer screening rates, and early adoption of novel biopsy technologies. Asia-Pacific is poised to be the fastest-growing region, fueled by increasing healthcare awareness, rising prevalence of GI disorders, and government support for diagnostic innovations.

Competitive Scenario:

Leading players in the Global EUS-Guided Fine Needle Biopsy Market include Boston Scientific Corporation, Olympus Corporation, Cook Medical, Medtronic, CONMED Corporation, and Medi-Globe Corporation. These companies are actively engaging in product innovations, strategic partnerships, and geographic expansion. For instance:

In 2023, Boston Scientific launched an enhanced version of its core biopsy needle, optimized for flexible endoscope compatibility.

Olympus Corporation collaborated with regional healthcare providers in 2024 to train clinicians on advanced EUS-FNB techniques.

Cook Medical expanded its distribution network across Asia-Pacific to meet rising demand.

Scope of Work – Global EUS-Guided Fine Needle Biopsy Market

Report Metric Details

Market Size (2023) USD 324 million

Projected Market Size (2031) USD 609 million

CAGR (2023–2031) 8.4%

Market Segments By System Type (Core Biopsy Needle, Aspiration Needle), By End-use, Region

Growth Drivers Rising prevalence of GI cancers, Minimally invasive diagnostics, EUS innovation

Opportunities AI integration, Emerging market adoption

Key Market Developments:

March 2023: Olympus introduced a next-generation linear EUS scope with enhanced needle guidance features for improved diagnostic accuracy.

July 2024: Medtronic unveiled a robotic-assisted EUS biopsy platform under clinical trials for real-time targeting of pancreatic lesions.

January 2025: Boston Scientific acquired a startup specializing in AI-powered biopsy image analytics, aiming to enhance EUS-FNB precision.

FAQs:

1) What is the current market size of the Global EUS-Guided Fine Needle Biopsy Market?

The market was valued at USD 324 million in 2023.

2) What is the major growth driver of the Global EUS-Guided Fine Needle Biopsy Market?

The major growth driver is the increasing prevalence of gastrointestinal and pancreatic cancers and the shift toward minimally invasive diagnostic procedures.

3) Which is the largest region during the forecast period in the Global EUS-Guided Fine Needle Biopsy Market?

North America is the largest region due to advanced healthcare systems and early adoption of diagnostic technologies.

4) Which segment accounted for the largest market share in the Global EUS-Guided Fine Needle Biopsy Market?

The core biopsy needle segment accounted for the largest share due to its superior tissue sampling capability.

5) Who are the key market players in the Global EUS-Guided Fine Needle Biopsy Market?

Key players include Boston Scientific Corporation, Olympus Corporation, Cook Medical, Medtronic, and CONMED Corporation.